Determination of free polysaccharide in Vi glycoconjugate vaccine against typhoid fever
نویسندگان
چکیده
منابع مشابه
Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China.
OBJECTIVE To test the efficacy of locally produced Vi vaccine over a time period of longer than one year. METHODS A double-blinded, randomized field trial was performed in Guangxi Zhuang Autonomous Region in south-western China, using 30 micrograms doses of locally produced Vi. Enrolled subjects were 3-50 years of age, although the majority (92%) were school-aged children, who have the highes...
متن کاملEfficacy of purified Vi polysaccharide typhoid vaccine.
This experiment was conducted to assess the efficacy of typhoid vaccine newly produced by purifying Vi antigen of Salmonella typhi. With Karber method, LD50 of challenging organism (S. typhi ty2) was determined as 6.31 CFU/mouse, and then the organism was used for the study. With Probits method, ED50 of the vaccine was determined as 0.016 microg / 0.5 ml / mouse. The ELISA titer (0.5097+/-0.060...
متن کاملMyD88-dependent pro-inflammatory activity in Vi polysaccharide vaccine against typhoid promotes Ab switching to IgG
Vi capsular polysaccharide is currently in use as a vaccine against human typhoid caused by Salmonella Typhi. The vaccine efficacy correlates with IgG anti-Vi Abs. We have recently reported that Vi can generate inflammatory responses through activation of the TLR2/TLR1 complex. In the present study, we show that immunization with Vi produces IgM as well as IgG Abs in wild type mice. This abilit...
متن کاملA conjugate vaccine against typhoid fever.
90 www.thelancet.com/infection Vol 14 February 2014 Zulfi qar Bhutta and colleages’ study in The Lancet Infectious Diseases marks an important milestone for the use of typhoid conjugate vaccines. Present Vi polysaccharide vaccines (Vi-PS) are not widely used because they cannot be given to children younger than 2 years and are thus excluded from the Expanded Programme of Immunization (EPI); fur...
متن کاملTyphim Vi vaccine against typhoid fever: a clinical trial in Kenya.
Safety, tolerance and immunogenicity of the purified Vi polysaccharide vaccine (Typhim Vi) against typhoid fever was evaluated in primary school children aged 5-15 years. A total of 435 children were vaccinated, each with a single intramuscular injection in the left deltoid muscle. One hundred and ten children were randomly selected for blood samples on day 0 (pre vaccination) and day 30 (post ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Pharmaceutical and Biomedical Analysis
سال: 2017
ISSN: 0731-7085
DOI: 10.1016/j.jpba.2017.02.042